Consider holding your next dose and contacting your prescriber if you experience severe or persistent gastrointestinal symptoms
Safety reporting : You can report any suspected side effects via the MHRA Yellow Card Scheme at www.mhra.gov.uk/yellowcard, contributing valuable information to ongoing drug safety monitoring
The studies demonstrated substantial weight reduction, along with significant improvements in several obesity-associated comorbidities, including knee osteoarthritis pain, moderate-to-severe obstructive sleep apnea (OSA), and type 2 diabetes
STORAGE of the of the Monoclonal Antibody to Glucagon Like Peptide 1 (GLP1) Store at 4C for frequent use
Follow our page for more such updates: News Source: #FDAApproval #LEROCHOL #LIBTherapeutics #PCSK9 #LDLCholesterol #Hypercholesterolemia #HeFH #CardiovascularHealth #Cardiology #LipidManagement #HeartHealth #Biologics #PharmaNews #DrugApproval To view or add a comment, sign in Novo Nordisk has announced that the US Food and Drug Administration (FDA) has approved the Wegovy pill, a once-daily oral semaglutide 25 mg, to reduce excess body weight, support long-term weight maintenance, and lower the risk of major adverse cardiovascular events